AIM: As tumor markers for pancreatic carcinoma, carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 have been used, but the sensitivity and specificity are not enough for the diagnosis of pancreatic carcinoma. METHODS: A novel serum tumor marker, RCAS1, was compared with two conventional serum tumor markers, CEA (highly specific for pancreatic cancer) and CA 19-9 (highly sensitive for pancreatic cancer), in 48 patients with pancreatic exocrine tumors. RESULTS: When the diagnosis of benign or malignant conditions was examined by one tumor marker, the sensitivity of RCAS1 alone (55%) was higher than that of CEA alone (27%) and the specificity of RCAS1 alone (92%) was greater than that of CA19-9 alone (78%). When examined by a combination of two markers, the sensitivity of a combination of RCAS1 and CA19-9 (95%) was superior to those of CA19-9 alone (78%), RCAS1 alone (55%, P = 0.002), CEA alone (27%) (P<0.001), RCAS1 and CEA (59%) and CA19-9 and CEA (82%). CONCLUSION: These results suggest that the combination of RCAS1 and CA19-9 is highly sensitive for pancreatic carcinoma.
AIM: As tumor markers for pancreatic carcinoma, carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 have been used, but the sensitivity and specificity are not enough for the diagnosis of pancreatic carcinoma. METHODS: A novel serum tumor marker, RCAS1, was compared with two conventional serum tumor markers, CEA (highly specific for pancreatic cancer) and CA 19-9 (highly sensitive for pancreatic cancer), in 48 patients with pancreatic exocrine tumors. RESULTS: When the diagnosis of benign or malignant conditions was examined by one tumor marker, the sensitivity of RCAS1 alone (55%) was higher than that of CEA alone (27%) and the specificity of RCAS1 alone (92%) was greater than that of CA19-9 alone (78%). When examined by a combination of two markers, the sensitivity of a combination of RCAS1 and CA19-9 (95%) was superior to those of CA19-9 alone (78%), RCAS1 alone (55%, P = 0.002), CEA alone (27%) (P<0.001), RCAS1 and CEA (59%) and CA19-9 and CEA (82%). CONCLUSION: These results suggest that the combination of RCAS1 and CA19-9 is highly sensitive for pancreatic carcinoma.
Authors: K Ohshima; K Muta; M Nakashima; S Haraoka; T Tutiya; J Suzumiya; C Kawasaki; T Watanabe; M Kikuchi Journal: Int J Cancer Date: 2001-07-01 Impact factor: 7.396
Authors: K Sonoda; T Kaku; T Hirakawa; H Kobayashi; S Amada; K Sakai; M Nakashima; T Watanabe; H Nakano Journal: Gynecol Oncol Date: 2000-12 Impact factor: 5.482
Authors: K Noguchi; M Enjoji; M Nakamuta; M Nakashima; H Nishi; I Choi; K Taguchi; K Kotoh; M Shimada; K Sugimachi; M Tsuneyoshi; H Nawata; T Watanabe Journal: Cancer Lett Date: 2001-07-26 Impact factor: 8.679
Authors: T Suzuki; S Inoue; W Kawabata; J Akahira; T Moriya; F Tsuchiya; S Ogawa; M Muramatsu; H Sasano Journal: Br J Cancer Date: 2001-11-30 Impact factor: 7.640
Authors: Leo Garcia Flores; Susanna Bertolini; Hsin Hsin Yeh; Daniel Young; Uday Mukhopadhyay; Ashutosh Pal; Yunming Ying; Andrei Volgin; Aleksandr Shavrin; Suren Soghomonyan; William Tong; William Bornmann; Mian M Alauddin; Craig Logsdon; Juri G Gelovani Journal: PLoS One Date: 2009-11-24 Impact factor: 3.240